For the remaining two patients whose tumors were ALK-I19–positive at diagnosis, the residual tumors became ALK-I19 negative, and ALK-negative by IHC and interestingly, most of the cells in these two post-chemotherapy tumor samples showed significant differentiation. The gene discussed is ALK; the disease is neoplasm.